Munich Reinsurance Co Stock Corp in Munich Purchases Shares of 1,584,714 Pfizer Inc. $PFE

Munich Reinsurance Co Stock Corp in Munich purchased a new stake in shares of Pfizer Inc. (NYSE:PFE) in the third quarter, according to the company in its most recent filing with the SEC. The firm purchased 1,584,714 shares of the biopharmaceutical company’s stock, valued at approximately $40,379,000.

Several other institutional investors also recently modified their holdings of the stock. Grey Fox Wealth Advisors LLC bought a new stake in Pfizer during the third quarter valued at approximately $29,000. Howard Hughes Medical Institute bought a new position in shares of Pfizer in the 2nd quarter worth $30,000. Darwin Wealth Management LLC purchased a new stake in shares of Pfizer during the 2nd quarter valued at $32,000. Evelyn Partners Asset Management Ltd bought a new stake in shares of Pfizer during the 2nd quarter worth $33,000. Finally, True Wealth Design LLC grew its position in Pfizer by 302.5% in the third quarter. True Wealth Design LLC now owns 1,296 shares of the biopharmaceutical company’s stock worth $33,000 after acquiring an additional 974 shares in the last quarter. 68.36% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of research analysts recently commented on PFE shares. Wolfe Research set a $24.00 target price on Pfizer and gave the company an “underperform” rating in a research note on Wednesday, December 17th. Barclays began coverage on Pfizer in a report on Thursday, February 19th. They issued an “underweight” rating and a $25.00 price objective for the company. UBS Group assumed coverage on Pfizer in a report on Tuesday, January 6th. They set a “neutral” rating and a $25.00 price objective on the stock. Royal Bank Of Canada assumed coverage on Pfizer in a research report on Tuesday, February 24th. They issued an “underperform” rating and a $25.00 target price for the company. Finally, Morgan Stanley cut their target price on Pfizer from $32.00 to $28.00 and set an “equal weight” rating for the company in a research note on Friday, December 12th. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, fourteen have issued a Hold rating and three have assigned a Sell rating to the company. According to MarketBeat.com, Pfizer currently has a consensus rating of “Hold” and an average target price of $28.05.

Pfizer Stock Performance

Shares of PFE stock opened at $27.07 on Friday. The company has a market capitalization of $153.93 billion, a P/E ratio of 19.90 and a beta of 0.47. Pfizer Inc. has a fifty-two week low of $20.92 and a fifty-two week high of $27.94. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.87 and a current ratio of 1.16. The stock has a 50 day moving average price of $26.30 and a two-hundred day moving average price of $25.47.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 EPS for the quarter, topping the consensus estimate of $0.57 by $0.09. Pfizer had a net margin of 12.42% and a return on equity of 20.48%. The company had revenue of $17.56 billion for the quarter, compared to the consensus estimate of $16.93 billion. During the same period in the previous year, the firm earned $0.63 earnings per share. The firm’s revenue for the quarter was down 1.2% on a year-over-year basis. Analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, March 6th. Stockholders of record on Friday, January 23rd were paid a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 6.4%. The ex-dividend date of this dividend was Friday, January 23rd. Pfizer’s dividend payout ratio is 126.47%.

Pfizer News Summary

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: China approved Pfizer’s GLP‑1 weight‑management drug (Xianweiying / ecnoglutide), opening a large new market for its obesity franchise and reinforcing Pfizer’s push into metabolic drugs — this expands addressable market and supports long‑term revenue potential. China approves Pfizer GLP-1 drug for weight management
• Positive Sentiment: Analyst upgrade: Argus Research upgraded PFE to Buy and set a $35 target, citing progress in the GLP‑1 program and oncology pipeline — this can attract buy interest and boost sentiment among dividend and income investors. Argus Turns Bullish on Pfizer
• Positive Sentiment: Oncology wins: positive Phase 3 EV‑304 PADCEV results and FDA full approval for BRAFTOVI combinations were highlighted as re‑framing Pfizer’s long‑term growth prospects in oncology — supports diversification away from COVID revenues. Pfizer Obesity Nod In China And Cancer Wins
• Positive Sentiment: Pipeline expansion in China: Pfizer launched a Phase 1 heart‑failure candidate study in China, signaling continued local R&D investment that could yield future launches in a large market. Pfizer Adds New Early-Stage Heart Failure Candidate
• Neutral Sentiment: Investor attention & valuation debate: multiple articles note heightened retail/institutional interest and divergent valuation views (trending stock coverage, DCF vs. long‑term return debates) — increases volatility/volume but not a direct fundamental change. Pfizer Is a Trending Stock
• Neutral Sentiment: Competition & generics risk for GLP‑1s: coverage notes Pfizer will face crowded competition (and price pressure risk) even as it gains approvals — a mixed commercial outlook. Weight-Loss Drug Approved in China — Up Against Generic Rivals
• Negative Sentiment: Structural headwinds remain: analysts reiterate risks from declining COVID revenues, upcoming patent expirations and U.S. drug‑pricing pressures (IRA) that could limit near‑term growth despite new launches. Can Pfizer Reignite Growth?
• Negative Sentiment: Policy/legal noise: a recent court ruling awarded Pfizer $29M in an SEC settlement dispute (one‑time benefit), but legal and policy developments remain sources of uncertainty for investors. Judge approves Pfizer, SEC settlement

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.